The estimated Net Worth of Bethany Sensenig is at least $13.9 Тысяча dollars as of 21 April 2023. Ms Sensenig owns over 9,100 units of 9 Meters Biopharma stock worth over $2,875 and over the last 3 years she sold NMTR stock worth over $11,011.
Ms has made over 1 trades of the 9 Meters Biopharma stock since 2023, according to the Form 4 filled with the SEC. Most recently she sold 9,100 units of NMTR stock worth $11,011 on 21 April 2023.
The largest trade she's ever made was selling 9,100 units of 9 Meters Biopharma stock on 21 April 2023 worth over $11,011. On average, Ms trades about 1,820 units every 0 days since 2022. As of 21 April 2023 she still owns at least 41,077 units of 9 Meters Biopharma stock.
You can see the complete history of Ms Sensenig stock trades at the bottom of the page.
Bethany Sensenig C.M.A., M.B.A. is the Chief Financial Officer at 9 Meters Biopharma.
Bethany's mailing address filed with the SEC is C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850.
Over the last 4 years, insiders at 9 Meters Biopharma have traded over $20,934,964 worth of 9 Meters Biopharma stock and bought 2,247,050 units worth $1,572,701 . The most active insiders traders include Israel Gp Ltd.Orbi Med Isra..., Mark A Sirgo и John Temperato. On average, 9 Meters Biopharma executives and independent directors trade stock every 35 days with the average trade being worth of $45,283. The most recent stock trade was executed by Bethany Sensenig on 21 April 2023, trading 9,100 units of NMTR stock currently worth $11,011.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
9 Meters Biopharma executives and other stock owners filed with the SEC include: